Delhi HC allows Dr. Reddy's to export diabetes drug semaglutide
Business
On March 9, 2026, the Delhi High Court ruled that Dr. Reddy's Laboratories can keep making and exporting semaglutide, a popular diabetes drug, to countries where it is not under patent.
The court decided Novo Nordisk's patent was not strong enough to block exports, since it was pretty much covered by an older, expired patent.
What's the impact?
Semaglutide (sold as Ozempic, Wegovy, and Rybelsus) is a big deal in the ₹1,446 crore GLP-1 market.
This ruling could boost India's role in supplying affordable generics worldwide and challenge how some pharma companies try to stretch patents longer than intended.
It could influence similar legal battles between generic makers and big pharma in other jurisdictions.